Having 27 years of experience in his field, he has treated above 2.000 patients. Other than BMT, he treats blood cancers (leukemia), MDS (Myelodysplastic Syndrome), lymph node cancers and myeloma.
Prof. Koç states that in 75% of all leukemia cases BMT treatment is preferred and in only 25% of the cases with low risk, chemotherapy can be applied. He adds that the BMT decision is given by the Committee at which genetic factors are also a determining factor.
Before the year 2000 as Prof. Yener Koç underlines, the treatment was very repressive due to high dose chemotherapy, but after the year 2000 thanks to new protocols with mini BMT procedures, it became possible to provide less dense treatments. He mentions his patients’ reactions and says: “While I am at visit after the procedure, I ask about how they feel during the procedure. They generally say that it was much easier than they expected”.
He puts emphasis on the recovery period since the patients are totally defenseless against infections at the first 6 months following the procedure and expresses the importance of close follow-up of the patient at this period.
Nearly 1/3 of Prof. Koç’s patients have been foreign patients from all around the world for the last 10 years. He not only treats them in Turkey but also trains and leads foreign hospitals to develop BMT programs just like HTMC in Tbilisi, Georgia.
Prof. Koç is also the leading pioneer of Haploidentical Transplant in Turkey. This treatment saves lives since there is no or much less waiting time for donors. Therefore losses while searching for the match can be prevented.
Although being the newest type of transplant, the professor adapted the method into his practice and produced over 80 international articles regarding the haploidentical methods. The success rate of the haploidentical is now almost the same as allogenic. The rejection rate of the method has dropped below 3% and it also became possible to treat patients over 60 (if their health scan results permit) who were inoperable in the past.